Lupus Foundation of America Greater Ohio Chapter Logo

Toll Free: 1 (888) NO-LUPUS
Phone: (440) 717-0183

Help Us Solve The Cruel MysteryTM

Donate To The Ohio Chapter

Investigational New Drug Application for ATA3219 Submitted to the FDA for Lupus Nephritis Treatment

by | Mar 1, 2024

Inside Lupus Research (ILR): Treatment News

A new drug application for the investigational therapy, ATA3219, for treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis) has been submitted to the U.S. Food and Drug Administration. 

ATA3219 is a CAR-T cell therapy. CAR-T cell therapy depletes disease-causing antibody producing cells and B cells (immune system cells involved in the production of autoantibodies and lupus disease activity). CAR-T cells are genetically-modified T-cells. T-cells are part of the immune system. To make CAR-T cells, scientists create or engineer new cells called chimeric antigen receptors (CARs), and then introduce T-cells into them. ATA3219 uses T-cells from other individuals (allogeneic) to target CD19, a protein found on the surface of B cells, and produces autoantibodies. 

Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.

Read the announcement

This post was originally published on this site

Skip to content